0000950170-24-090257.txt : 20240802
0000950170-24-090257.hdr.sgml : 20240802
20240802213218
ACCESSION NUMBER: 0000950170-24-090257
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240801
FILED AS OF DATE: 20240802
DATE AS OF CHANGE: 20240802
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Young Jonathan
CENTRAL INDEX KEY: 0001779805
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 241172957
MAIL ADDRESS:
STREET 1: C/O AKERO THERAPEUTICS, INC.
STREET 2: 170 HARBOR WAY 3RD FL
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
ownership.xml
4
X0508
4
2024-08-01
0001744659
Akero Therapeutics, Inc.
AKRO
0001779805
Young Jonathan
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO
CA
94941
false
true
false
false
Chief Operating Officer
true
Common Stock
2024-08-01
4
S
false
3031
26.44
D
243823
D
Common Stock
2024-08-01
4
S
false
1969
27.23
D
241854
D
Common Stock
20000
I
By EA Irrevocable Trust
Common Stock
20000
I
By CM Irrevocable Trust
Common Stock
20000
I
By JL Irrevocable Trust
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 27, 2023, previously adopted by the Reporting Person.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.19 to $26.81, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2).
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.91 to $27.88, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3).
These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
/s/ Jonathan Young, Attorney-in-Fact
2024-08-02